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ABSTRACT
Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive 
subtype of renal cancer. STAT3 pathway is altered in these tumors and p-STAT3 
Ser727 is an independent prognostic factor for ccRCC. Protein kinase CK2 is altered 
in different types of tumors and overexpression of CK2α is considered predictive 
of bad prognosis and metastatic risk. CK2 subunits analyses in ccRCC samples 
showed increased CK2α/α’ nuclear content in all cases, but decreased cytosolic CK2β 
(CK2βcyt) levels in the more advanced tumors. Stable downregulation of CK2β in 
renal proximal tubular (HK-2) and clear cell adenocarcinoma (786-O) cells triggered 
changes in E-cadherin, vimentin and Snail1 protein levels indicative of epithelial-to-
mesenchymal transition (EMT), and increased HIF-α. Moreover, CK2β was required 
in order to observe STAT3 Ser727 phosphorylation in HK-2 but not in 786-O cells. 
We also observed that CK2β improved the prognostic value of p-STAT3 Ser727, as 
CK2βcyt>41 (median value) discriminates patients free of disease for a period of 10 
years upon surgery, from those with CK2βcyt<41, when p-STAT3 Ser727levels are low. 
We conclude that CK2β down-regulation might represent a mechanism to support 
EMT and angiogenesis and that CK2βcyt levels are instrumental to refine prognosis 
of ccRCC patients with low p-STAT3 Ser727 levels.
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INTRODUCTION
Renal cell carcinoma (RCC) is the sixteenth most 
common cause of death from cancer worldwide and 
its incidence and mortality rates have been increasing 
in many countries in the last years [1, 2]. The clear 
cell RCC (ccRCC) is the most frequent RCC subtype, 
comprising 80–90% of the malignant renal tumors in 
adults [3]. Originated from renal cells of the proximal 
convoluted tubule, ccRCC is characterized by the absence 
of symptomatology until advanced stages of the disease, 
what is associated with a poor prognosis [4]. ccRCC is 
highly resistant to radiotherapy and to conventional 
cytotoxic chemotherapy. Albeit novel targeted therapies 
have been implemented since 2008, treatment resistance 
remains a problem for treatment of metastatic patients 
what makes surgical resection the most common treatment 
for localized disease [3]. However, approximately one-
third of the patients have metastatic disease detected 
at presentation, and 20 to 30% of all ccRCC patients 
undergoing nephrectomy exhibit local or distant disease 
recurrence during the follow-up. Patients with distant 
metastases have a poor prognosis and their 5-year survival 
rate is reduced to around 10%. 
Epithelial-to-mesenchymal transition (EMT), a 
well characterized process in embryogenesis and wound 
healing, has also been linked to tumor progression and 
metastasis in a wide number of carcinomas including 
RCC [5, 6]. Several signaling pathways, including hypoxia 
(HIF1/2) pathway are inducers of the EMT phenotype [7] 
and it is well known that ccRCCs display deregulation of 
HIF1/2 pathway [8, 9]. The signal transducer and activator 
of transcription-3 (STAT3) pathway is also deregulated 
in human RCC [10] and STAT3 has been reported to act 
as a potent regulator of HIF-1α and HIF-2α expression 
[11] and as a modulator of HIF-1-mediated response [12]. 
STAT3 activation is reflected through its phosphorylation 
at Tyr705 and Ser727 residues, both of which are increased 
in ccRCC tumors. In fact, we have recently shown that 
p-STAT3 Ser727 is an independent prognostic factor for 
ccRCC patients [13]. 
Different reports have shown that protein kinase 
CK2 is involved in HIF-1α activation and stabilization 
[14–16]. Moreover, CK2 activity is necessary for STAT3 
activation by IL-6 family cytokines [17] and cell treatment 
with CK2 inhibitors affect  STAT3 phosphorylation on 
Ser727 [18, 19]. CK2 is a constitutively active serine/
threonine kinase present in all eukaryotic organisms which 
acts on a large number of protein substrates involved in a 
plethora of cellular functions [20]. In mammals, CK2 is 
composed of two catalytic (CK2α and CK2α’) and a dimer 
of regulatory subunits (CK2β) giving rise to different 
heterotetrameric forms of the holoenzyme (α2β2, αα’β2 and 
α’2β2) [21–23]. The CK2α and CK2α’ show high similarity 
in their structural and enzymatic characteristics. Besides 
its central role in assembling CK2 holoenzyme, CK2β 
also plays an essential role in the aggregation of CK2 
holoenzyme into less active/inactive polymeric assemblies 
which support an autoinhibitory mechanism of regulation 
of CK2 [22]. In addition, CK2β helps to discriminate 
between protein substrates whose phosphorylation is 
specifically catalyzed by either the free catalytic subunits 
or CK2 holoenzyme. Interestingly, CK2 holoenzyme 
is required to phosphorylate snail1 what primes its 
subsequent phosphorylation by GSK3β, a process that 
targets it for degradation [24]. Moreover, downregulation 
of CK2β was enough to stabilize snail1 and to induce an 
EMT-like phenotype in normal human breast epithelial 
cells (MCF10A cells) [24].
Increased expression of CK2 catalytic subunits has 
been shown to occur in different types of human tumors, 
including renal carcinoma [25–27], and overexpression 
of both CK2α and CK2α’ is considered as predictive 
of bad prognostic and metastatic risk [27–33]. The 
information concerning CK2β status in cancer is rather 
scarce. A preliminary report indicated that in human renal 
carcinoma the regulatory CK2β subunit increased even 
in higher amounts than the catalytic CK2α subunit [25]. 
In contrast, a recent report using a set of fifteen human 
renal cell carcinoma cell samples analyzed by western blot 
detected decreased CK2β levels in some of those samples 
[26]. However, the correlation between CK2β protein 
levels and the clinicopathological characteristics of the 
RCC remains unexplored.  
In the present work we aimed to analyze the potential 
correlation of CK2 subunits with the clinicopathological 
characteristics of ccRCC tumors and patient survival 
as well as their impact in HIF expression and STAT3 
phosphorylation in human renal cell lines. The results 
obtained in our work indicate that in ccRCC, CK2 shows 
not only alterations in the expression of the two catalytic 
(CK2α’/CK2α) subunits but also in the regulatory CK2β 
subunit. Moreover, the stable silencing of CK2β in human 
renal cell lines increases HIFα expression and affects 
STAT3 phosphorylation. In addition, our results show that 
cytosolic CK2β levels help to refine the prognostic value 
of pSer727-STAT3 in ccRCC patients.
RESULTS
The expression of CK2 subunits shows 
asymmetric changes in ccRCC tumor 
progression
A preliminary analysis by western blot of CK2 
subunits in a set of frozen tissue samples from patients with 
ccRCC showed that they did not follow similar patterns 
along ccRCC tumor progression (Figure 1, Supplementary 
Figure 1 and Supplementary Table 1). CK2α (1AD9 
antibody) and CK2α’ mean values increased in tumor 
samples of low Fuhrman grade tumors (G1/G2) with 
respect to normal tissue (set up as fold change of 1) and the 
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increases were even more marked in the G3/G4 group. The 
CK2α’ values in the G3/G4 tumors were dispersed and the 
number of tumors too low to reach statistical significance 
when compared with values observed in G1/G2 tumors. 
The values shown by the tumors (G1/G2 or G3/G4) were 
statistically significant respect to values found in normal 
tissues but they did not reach statistical significance when 
compared between different tumor groups. On the other 
hand, CK2β subunit (6D5 antibody) increased in the 
G1/G2 group but decreased in the more advanced tumors 
(G3/G4). A similar trend was detected when the samples 
were combined according to their tumor stage in pT1/
pT2 and pT3 groups. Bands detected for CK2α, CK2α’ 
and CK2β in the immunoblots of Figure 1 have been also 
found in the 786-O cell line (Supplementary Figure 1). It 
is likely that extra bands detected in western blots with 
Figure 1: Protein kinase CK2 subunits expression in different extracts of human ccRCC biopsies. (A) Western blot 
analysis of CK2α, CK2α’, CK2β and β-actin expression levels in tissue extracts of representative tumor (T) and unaffected normal (N) 
kidney counterpart samples from ccRCC patients. The type of antibody used to detect each CK2 subunit is indicated in parenthesis. 
Samples are classified by their grade (G1 to G4) and tumor stage (pT1 to pT3). (B), (C) Expression ratios of CK2 subunits between tumor 
and unaffected normal kidney counterpart samples from ccRCC patients, classified by their Fuhrman nuclear grade (B) or their tumor stage 
(C). Bar graphs show the fold change in CK2α, CK2α’ and CK2β subunit expression in tumors respect to normal kidney counterpart (T/N 
ratios) after normalization to their β-actin content. Data are represented as mean +/- SEM. Values were analyzed by Student’s t-test. (*), (**), 
(***) denote p < 0.05, p < 0.01 and p < 0.001, respectively. Non-significant differences are not indicated. 
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the anti-CK2α (1AD9 antibody) antibody correspond to 
proteolytic CK2α products.
In order to use a larger number of ccRCC tumor 
samples, we decided to evaluate CK2α/α’ and CK2β 
subunits by immunohistochemistry in tissue microarrays 
(TMA) including tumor and normal counterpart renal 
tissue samples and the results were correlated with tumor 
characteristics. The TMA used included 98 ccRCC 
patients with the following characteristics: 57.1% men 
and 42.9% women, median age: 64 years range: 25 
to 86. Tumor was right side in 59.1% cases and left in 
40.8% cases. Incidental presentation was found in 52.5% 
patients and 46.9% were symptomatic. 87.9% presented 
with localized tumors and 11.1% with metastasis. 
92.9% patients underwent radical nephrectomy, while 6 
underwent nephron-sparing surgery. Median tumor size 
was 6.4 cm (range 1.5 to 16). Fuhrman grade was I (G1) in 
20.4%, II (G2) in 41.8%, III (G3) in 24.4% and IV (G4) in 
13.2%. The most frequently observed pT stages were pT1a 
in 26.5% and pT1b in 27.5%. Lympho-vascular invasion 
was present in only 5.1% of patients. Finally, UICC risk 
group was I in 72.4 % and II in 27.5 % of patients studied.
Representative images of ccRCC tumors and 
unaffected normal kidney counterparts, stained with 
specific antibodies against CK2α and CK2β, are shown 
in Figure 2. The anti-CK2α/α’ (H-286) and anti-CK2β 
(6D5)  antibodies have been used in previous IHC 
studies [29, 34, 35].  The specificity of the anti-CK2β 
antibody (6D5) was also assessed by antibody depletion 
experiments (Supplementary Figure 2). Positive cytosolic 
and nuclear staining for CK2α/α’ and CK2β was detected 
in renal tubular cells in normal counterpart renal tissue 
(Figure 2A). CK2α/α’ staining in tumor core samples 
tended to show a prominent nuclear staining (Figure 
2A). When analyzing the TMA results according to the 
tumor Fuhrman grade, we observed that the mean H-Score 
values for nuclear CK2α/α’ staining were significantly 
higher in tumors than in normal counterpart renal tissue 
whereas cytosolic CK2α/α’ staining in tumor samples 
decreased slightly although the differences were not 
statistically significant (Figure 2B, left panel). These 
results would agree with a specific nuclear accumulation 
of CK2α/α’ in ccRCC, as reported recently [27]. It 
is worth to mention that the results in Figure 2B show 
the expression levels of both catalytic subunits in two 
different cellular compartments using the H-score method, 
while in the western blot assays shown in Figure 1 CK2α 
and CK2α’ levels were analyzed separately but in a total 
cellular lysate. Therefore, the augmented values for the 
CK2α’ subunit observed in Figure 1 might relate to the 
contribution of the augmented expression of this subunit 
in the nuclei. 
In contrast to CK2α/α’, nuclear CK2β staining 
showed only moderate increases in tumor samples whereas 
cytosolic CK2β showed a significant decline in G1/G2 that 
was particularly marked in G3/G4 samples (Figure 2C, left 
panel). When the samples were grouped according to their 
tumor stage (pT1/pT2 and pT3/pT4) the trend of changes 
in CK2α/α’ mirrored that detected when grouped by grade. 
A similar observation was evident concerning CK2β levels 
(Figure 2B and 2C). 
The behavior of CK2β subunit in tumors has 
been less explored, in contrast to the well characterized 
increases in CK2 catalytic subunits (CK2α/α’) in diverse 
types of carcinomas. A critical point addressed in our 
study was if the profile of CK2β changes mirrored or not 
that of CK2 catalytic subunits as indicative of potential 
changes in tetrameric CK2 form. Our results would agree 
with increases in CK2 holoenzyme in the initial stages of 
ccRCC but not in the more advanced tumors, regardless 
of the changes in the individual CK2α or CK2α’ subunits, 
since both were found increased at the initial and advanced 
ccRCC tumor stages.
Downregulation of CK2β in HK-2 and 786-O 
renal cell lines decreases specifically the activity 
of CK2 holoenzyme 
Human renal cell line 786-O is a widely used 
model of human ccRCC cells, whereas HK-2 cells are a 
well-established model of non-malignant human kidney 
PTC cells. Both cell lines express the two CK2 catalytic 
subunits (CK2α, and CK2α’) as well as the regulatory 
CK2β (Supplementary Figure 3). However, the levels of 
CK2α and CK2α’ were slightly higher (1.4 to 1.7-fold) in 
786-O cells than in HK-2 cells whereas CK2β levels were 
similar. Increases in the ratios between CK2 catalytic and 
regulatory subunits have also been observed in metastatic 
breast cancer cell lines as compared with non-malignant 
mammary gland epithelial cells [36].
Lentiviral transduction of shRNA-CK2α caused the 
stable silencing of CK2α to about 40–50% of the initial 
value both in 786-O and HK-2 cell lines, as compared with 
their respective empty-vector transduced cells (shCV) 
(Figure 3A). CK2α-silencing had minor consequences 
in CK2α’ levels but was accompanied with a decrease in 
CK2β levels to about 60% in 786-O and to 40% in HK-2 
cells. Decreases in CK2β levels in response to CK2α-
silencing have also been reported previously in other 
cell types due to the instability of CK2β once free [37, 
38]. Lentiviral transduction of shRNA-CK2β provoked 
a decrease in CK2β to about 30% of the initial value in 
786-O and to less than 10% in HK-2 cells. As observed in 
other cell lines [37, 38], CK2β-silencing caused a decrease 
in CK2α’. In contrast, CK2α levels were essentially 
unaffected in CK2β-silenced cells. 
The consequences of the changes in the cell levels of 
CK2 catalytic/regulatory subunits on its activity was first 
determined in cell extracts using an in-gel CK2 activity 
assay with β-casein as substrate. As shown in Figure 3B, 
the extent of β-casein phosphorylation detected in these 
assays correlated with the amount of catalytic subunit, 
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Figure 2: Expression of CK2 subunits in the 98 ccRCC samples embedded in Tissue Microarrays (TMAs). (A) CK2α and 
CK2β levels in tumor tissue samples classified according their nuclear Fuhrman Grade. The pictures correspond to representative samples 
from biopsies of patients affected by ccRCC with different Fuhrman grades (G1 to G4) as well as a sample of unaffected normal kidney 
counterpart out of the 98 samples included in the TMA. CK2 subunits (brown) were detected by a colorimetric method and the samples 
were counterstained by haematoxylin as was indicated in materials and methods. (B), (C) Scatter plot of CK2α and CK2β expression levels 
in the nuclei (Nuc) and cytoplasm (Cyt) of the 98 ccRCC samples included in TMAs classified by their Fuhrman nuclear grade (G1/G2, G3/
G4) (left hand panels) and stage (pT1/pT2, pT3/pT4) (right hand panels). The samples were evaluated using the H-score semi-quantitative 
method described previously. H-score values obtained were analyzed by one-way ANOVA using the Bonferroni’s correction algorithm. 
(**), (***) denote p < 0.01 and p < 0.001, respectively. Non-significant differences are not indicated.
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either CK2α or CK2α’ detected by western blot. We have 
previously shown that the standard CK2 peptide (CK2-
tide) is a substrate for both CK2 holoenzyme and free 
catalytic subunits whereas the phosphorylation of the 
eIF2β derived peptide (eIF2β-tide) shows an absolute 
requirement for CK2β [39]. CK2 activity assays in 
crude cell extracts from both the HK-2 and the 786-
O cell lines showed that the negative consequences 
of CK2α-silencing were more marked than those of 
CK2β-silencing when using the CK2-tide whereas those 
caused by CK2β-silencing were more evident on eIF2β-
tide (Figure 3C). The combined data obtained on CK2 
subunits content and activity assays indicate that CK2 
present in CK2α-downregulated cells would correspond 
to CK2 holoenzyme, either tetramers or other higher 
rank structures, whereas the CK2β-downregulated cells, 
in particular the HK-2/shCK2β cells, would contain low 
amounts of CK2 holoenzyme which would be responsible 
for the activity on the eIF2β-tide. 
We also verified the reduction of CK2 activity in 
the downregulated cells by means of the endogenous 
substrate Akt1 Ser129 [40]. Its phosphorylation was 
reduced in HK-2 cells by down-regulation of CK2 
subunits, especially CK2β (Figure 3D), suggesting that it 
requires the holoenzyme form of CK2. This agrees with 
that observed recently in C2C12 myoblast cell line after 
knocking out CK2 subunits [38]. In the case of 786-O 
cells, the mainly expressed Akt isoform is Akt2, which 
is not phosphorylated by CK2 [41], thus phosphorylation 
of Akt1 at Ser129 was hardly appreciable; nevertheless it 
was also reduced by down-regulation of CK2 subunits, 
especially of CK2β.
CK2α- or CK2β-downregulation alters the 
expression of EMT markers in HK-2 and 786-O 
cells
Recent reports have shown CK2 holoenzyme 
activity contributes to maintaining a normal epithelial 
morphology in breast cell lines, as CK2β silencing 
induced an epithelial-to-mesenchymal transition (EMT) 
phenotype [24, 36, 42] associated with decreases in 
E-cadherin and increases in snail1 and vimentin levels. 
We decided to check if the decreases in CK2 holoenzyme 
caused by downregulation of either CK2α or CK2β altered 
the protein levels of these EMT markers in HK-2 and 
786-O renal cell lines with respect to their corresponding 
controls (shCV). Control HK-2 cells expressed significant 
levels of E-cadherin whereas 786-O cells expressed very 
low levels, which were only detectable after long exposure 
of the blot (Figure 4A). In both cell lines, silencing 
of CK2α, and in particular of CK2β, caused a marked 
decrease in E-cadherin. Snail1 is a well-known repressor 
of E-cadherin expression whose stability in MCF10A cells 
is controlled through hierarchical phosphorylation by CK2 
and GSK3β, a process that depends strongly on CK2β 
levels [24]. In agreement with this, CK2β silencing caused 
an increase in snail1 protein levels in 786-O and in HK-2 
cells although both basal and stimulated levels were more 
robust in 786-O cells (Figure 4A). Intermediate increases 
in snail1 were detected in both cell lines after CK2α-
silencing what agrees with the intermediate decreases in 
E-cadherin levels detected after silencing this subunit. 
Vimentin is a positive EMT marker whose expression is 
enhanced by snail1 [43]. Control HK-2 and 786-O cells 
expressed detectable levels of vimentin, which increased 
in the CK2-silenced cells. 
The most dramatic effects on these EMT markers 
were exerted by CK2β down-regulation and they were 
particularly evident on E-cadherin and snail1 in the HK-2 
cell line. The effect of rescuing CK2β levels in HK-2/
shCK2β cells was then studied in order to confirm the 
specificity of the effects on E-cadherin and snail1. To 
this purpose, HK-2 cells were transfected with a vector 
containing a synthetic CK2β optimized coding sequence 
carrying base mutations that would weaken its recognition 
by the shCK2β without introducing any mutation into 
the CK2β expressed protein. Overexpression of CK2β 
in control HK-2/shCV cells did not alter snail1 and 
E-cadherin levels, whereas an increase in E-cadherin and 
a decrease in snail1 levels were detected in the transfected 
HK-2/shCK2β cells (Supplementary Figure 4). These 
results agree with those reported previously in MCF10A 
cells [24].
Previous reports have shown that HIFα is 
upregulated in ccRCC and could be involved in the 
induction of an EMT phenotype in renal cell lines 
[44, 45]. On the other hand, CK2 activity has been shown 
to affect HIF-1α transcriptional activity and to stabilize 
HIF-1α protein [15, 16, 46]. Therefore we decided 
to explore the potential effects of CK2 holoenzyme 
downregulation through CK2α- or CK2β-silencing on 
HIFα expression in HK-2 and 786-O cells under the 
normoxic conditions used throughout our studies. HIF-1α 
levels, the sole isoform of HIFα expressed in HK-2 cells, 
were very low in control cells, did not essentially vary 
in CK2α-silenced cells but tended to increase in CK2β-
silenced HK-2 cells (Figure 4B). On the other hand, 786-O 
cells are known to express only the HIF-2α isoform. HIF-
2α levels did not change in CK2α-silenced cells but were 
significantly higher in CK2β-silenced 786-O cells. 
CK2β-downregulation affects STAT3 
phosphorylation in HK-2 and 786-O cells
STAT3 phosphorylation has been shown to affect 
HIF-2α levels in 786-O cells and HIF-1α and HIF-
2α in Caki-1 renal cancer cells [11, 47], and STAT3 
phosphorylation at Tyr705 and Ser727 residues is 
increased in ccRCC tumors [13]. Previous reports have 
shown that exposure of cells to CK2 chemical inhibitors 
(which block the activity of both CK2 holoenzyme and 
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free catalytic subunits) TBB  or CX-4945  diminished 
p-STAT3 Tyr705 [17, 37] as well as p-STAT3 Ser727 
phosphorylation in response to different stimuli [18, 19]. 
More recently, recombinant human CK2 holoenzyme 
has been shown to phosphorylate ‘in vitro’ recombinant 
human STAT3 on Ser727 but the potential role of CK2β in 
regulating STAT3 phosphorylation, in particular at Ser727, 
was not evaluated [48]. Hence, we decided to determine 
if CK2β affected p-STAT3 Tyr705 and p-STAT3 Ser727 
levels in the cultured renal cells. 
In HK-2 cells p-STAT3 Tyr705 levels tended to 
increase in CK2α-silenced cells and in particular in 
CK2β-silenced cells (Figure 5). In contrast p-STAT3 
Ser727 levels tended to decrease after CK2α silencing 
and decreased significantly after CK2β silencing. 
Downregulation of CK2α did not significantly alter 
STAT3 phosphorylation at Tyr705 in 786-O cells whereas 
CK2β downregulation caused a small but significant 
increase in p-STAT3 Tyr705. Interestingly, in this cell line 
downregulation of CK2α also caused a small decrease in 
Figure 3: Effects of CK2α or CK2β-downregulation on CK2 subunits levels and CK2 activity in HK-2 and 786-O cell 
lines. (A) Western blot analysis of CK2α, CK2α’ and CK2β expression levels in HK-2 and 786-O cells lines silenced for either CK2α 
or CK2β subunits. The type of antibody used to detect each CK2 subunit is indicated in parenthesis. Values below each band correspond 
to the relative subunit expression level respect to their corresponding control cell line (either HK-2 shCV or 786-O shCV). (B) In-gel 
CK2 activity assay with β-casein as substrate. (C) CK2 activity of silenced cell lines using either the CK2-tide (phosphorylated by the 
holoenzyme and catalytic subunits) or the eIF2β-tide (phosphorylated by CK2 holoenzyme). Data are represented as mean +/- SEM. (D) 
Effects of CK2α or CK2β-downregulation on Akt1 phosphorylation at Ser129. Akt1 phosphorylation at its Ser129 (p-Akt S129) and total 
Akt1 and Akt2 levels were detected in cell extracts from HK-2 and 786-O cells lines silenced for either CK2α or CK2β subunits by western 
blot using specific antibodies. Values below each band correspond to the relative protein expression level respect to their corresponding 
control cell line (HK-2 shCV and 786-O shCV). 
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p-STAT3 Ser727 levels, whereas downregulation of CK2β 
did not decrease them. These results suggest that, unlike 
the HK-2 cells, the tumorigenic 786-O cells do not depend 
on CK2β for sustaining p-STAT3 Ser727 levels.  
Cytosolic CK2β levels help to refine the 
prognostic value of pSer727-STAT3 in ccRCC 
patients
When the data from the ccRCC TMAs were grouped 
by Fuhrman grade or stage no differences were found for 
the CK2α/α’ subunits, either nuclear or cytosolic, among 
groups but a clear tendency was observed for high grade 
and high stage tumors expressing low levels of cytosolic 
CK2β subunit. In the multivariate analysis, using an 
H-Score threshold of cytosolic CK2β higher or equal 41 
(median value), we observed a non-significant correlation 
(p = 0.703) with patient survival, which indicates that 
cytosolic CK2β (CK2βcyt) by itself is not useful as a 
prognostic biomarker of ccRCC. We have previously 
demonstrated that p-STAT3 Ser727 is an independent 
prognostic factor for ccRCC patients [13]. Since we have 
now observed that CK2 affects STAT3 phosphorylation we 
decided to evaluate whether a correlation between CK2 
subunits expression and p-STAT3 Ser727 levels exists.  
When analyzing all patients together, we observed a 
negative but non-significant correlation between p-STAT3 
Ser727 and cytosolic CK2β with Spearman Index of 
-0.057. Although the correlation was weak between both 
factors, we aimed to explore the impact, if any, of CK2βcyt 
higher or equal 41 (median value) on the survival profile 
of patients with p-STAT3 Ser727 levels >100 or <100, 
which were previously correlated with poor or good 
prognosis, according to patient survival, respectively 
[13]. We observed that the worst possible combination 
corresponds to p-STAT3 Ser727 >100, as reported, with no 
Figure 4: Expression of EMT markers and HIFα in HK-2 and 786-O cells silenced for CK2 subunits. (A) Western blot 
analysis of the epithelial (E-cadherin) and mesenchymal markers (Vimentin, Snail1) in HK-2 and 786-O cell lines silenced for either CK2α 
or CK2β subunits. Values below each band represent the relative protein expression level respect to their corresponding control cell line 
(HK-2 or 786-O shCV). (B) Effect of CK2α or CK2β-downregulation on the relative expression of HIF1α in HK-2 cells and of HIF2α in 
786-O cells. Values below each band represent the relative protein expression level respect to their corresponding control cell line (HK-2 
or 786-O shCV).
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major contribution of CK2βcyt, since Kaplan Meier curves 
were alike when CK2βcyt was <41 or >41 (Figure 6A). 
Accordingly, we could say that when taking all the patients 
into consideration, without any kind of stratification, 
CK2βcyt does not add extra prognostic information to what 
the high levels of p-STAT3 Ser727 alone predict, regarding 
poor patient survival. Nevertheless, it is remarkable 
to observe that for patients with low p-STAT3 Ser727 
levels, thereby with good prognosis according to this 
biomarker, those with low CK2βcyt levels (<41) (Figure 
6A) exhibited a similar survival rate than patients with 
high pSer727-STAT3 levels. When patient represented 
in Figure 6A corresponding to the pSer727-STAT3>100/
CK2βcyt>41; pSer727-STAT3>100/CK2βcyt<41 and 
p-STAT3 Ser727<100/CK2βcyt<41 groups were combined 
(COMB2), significant statistical differences (p = 0.043) 
appeared with the p-STAT3 Ser727<100/ CK2βcyt>41 
patient group (COMB1) (Figure 6B). Accordingly, we can 
say that CK2βcyt refines the prognostic value of p-STAT3 
Ser727 in patients with apparent good prognosis according 
to their low p-STAT3 Ser727 levels.
The prognostic value of p-STAT3 Ser727 was 
highly significant and even more pronounced in high-risk 
patients, were survival after 10-year follow-up was HR 
= 3.32 (95%IC 1.26–8.71) p = 0.014, by a multivariate 
analyses [13]. When analyzing the prognostic value of 
the combined biomarkers in separated high- and low-risk 
groups of patients, we observed that while in the low-
risk patients no significant differences (p = 0.850) were 
observed between COMB1 and COMB2 markers (Figure 
6C), a striking significant difference (p = 0.031) was 
observed for patients in the high-risk group according to 
COMB1 or COMB2 markers (Figure 6D). Kaplan Meier 
curves indicated that patients with p-STAT3 Ser727<100/
CK2βcyt>41 (COMB1) were free of disease with no 
events in 10 years post-surgery, while those with p-STAT3 
Ser727<100/CK2βcyt<41 were falling to profiles similar 
to patients with high p-STAT3 Ser727 levels. To sum up, 
our results indicate that CK2βcyt can refine the prognostic 
value of p-STAT3 Ser727 in patients within the high risk 
group, and that patients with high CK2βcyt have better 
prognosis than those with low CK2βcyt levels when 
p-STAT3 Ser727 are low (<100).
DISCUSSION
Different reports have shown a link between the 
expression of CK2 catalytic subunits (CK2α/α’) and 
diverse types of carcinomas [26–32, 49, 50], The results of 
our study agree with an increase in nuclear CK2 catalytic 
subunits content in ccRCC, as previously reported in other 
human cancers [27, 28, 32, 49]. On the other hand, studies 
on the status of the regulatory CK2β in cancer are rather 
scarce. Our data on western blot analysis partially agree 
with those of a previous report, published two decades 
ago [25], since we detected increased total CK2β levels 
in the G1/G2 tumor samples. However, this does not hold 
for the ccRCC samples corresponding to more advanced 
tumors (G3/G4 and pT3), which showed decreases in 
total CK2β levels when analyzed by western blot or 
more specifically in cytosolic CK2β when analyzed by 
immunohistochemistry. Increased ratios between catalytic 
Figure 5: Effects of CK2α or CK2β-downregulation on STAT3 phosphorylation in HK-2 and 786-O cells. STAT3 
phosphorylation at either Tyr705 (p-STAT3 Y705) or Ser727 (p-STAT3 S727) and total STAT3 levels were detected in cell extracts from 
HK-2 and 786-O cells lines silenced for either CK2α or CK2β subunits by western blot using specific antibodies. The plots indicate the 
mean values of the densitometries of the p-STAT3 bands relative to the total STAT3 levels obtained in four different experiments. Data are 
represented as mean ± SEM. Values were analyzed by Student’s t-test. (*) and (****) denote p < 0.05 and p < 0.0001, respectively.
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and regulatory subunits, due in part to decreased levels 
of the regulatory CK2β subunit, has also been detected 
previously in five out of a set of fifteen human renal cell 
carcinoma cell samples analyzed by western blot [26]. 
Moreover, a marked downregulation of CK2β mRNA 
expression in all tumor samples compared with normal 
renal tissue was detected in that study [24] suggesting an 
important posttranscriptional regulation of CK2 subunits 
in RCC. In contrast to this, a more recent study [27] 
has shown that CK2β mRNA expression was slightly 
higher in ccRCC than in renal cortex but no correlation 
was observed between CK2β mRNA expression and 
clinicopathological factors. However, the protein levels of 
CK2β were not determined in these studies. Our results 
show low levels of cytosolic CK2β subunit in high grade 
and high stage tumors, as discussed later in more detail. 
The asymmetric changes in CK2 subunits detected 
in the ccRCC samples would reflect alterations in the 
Figure 6: Kaplan-Meier estimates of 120-months overall survival according to combinations of p-STAT3 Ser727 and 
CK2βcyt expression levels. (A) Patients exhibiting p-STAT3 S727 levels <100 and >100, correlating with good and bad prognosis, 
respectively [13], were subgrouped according to their CK2βcyt levels were above or below 41 (median value). Metastatic patients have 
been excluded. (B) COMB1 corresponds to patients exhibiting p-STAT3 S727 levels <100 and CK2βcyt >41. COMB2 includes the three 
other groups. No significant differences were observed among groups in COMB2. Statistical significant differences were observed between 
COMB1 and COMB2. (C, D) Kaplan-Meier estimates of 120-months overall survival according to COMB1 or COMB 2 for Low Risk 
(C) and High Risk (D) patients. Statistical significant differences were observed between COMB1 and COMB2 in the High Risk group. 
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ratio of CK2 catalytic subunits incorporated into CK2 
holoenzyme, what could alter the targeting of a subset of 
CK2 specific substrates [51, 52]. As reported previously 
for normal human breast epithelial cells (MCF10A cells) 
[24], depletion of CK2β in HK-2 and 786-O cells altered 
the expression of EMT markers, decreasing E-cadherin 
and increasing snail1 and vimentin levels. These effects, 
together with the specific decrease in CK2 activity on the 
eIF2β-tide, without altering that on the CK2-tide, would 
support a marked specific decrease in CK2 holoenzyme 
in the silenced cells. On the other hand, down-regulation 
of CK2α induced a partial change in these parameters, 
indicative of intermediate decreases in CK2 holoenzyme. 
Altogether, our results suggest that the decreases in CK2β 
might contribute to the EMT in RCC tumors, a process 
suggested to play a significant role in disease recurrence, 
invasion and metastasis [6].
It is well known that ccRCC are highly vascularized 
tumors. Accordingly, angiogenesis is considered 
fundamental to ccRCC pathogenesis and HIFα is 
upregulated in these tumors [8, 9]. Protein kinase CK2 has 
been shown to affect HIF-1α transcriptional activity [46] 
and to stabilize HIF-1α protein either by phosphorylation 
or destabilization of VHL protein [15, 16] or through 
the histone deacetylase (HDAC)-mediated pVHL down-
regulation pathway [14]. Interestingly, free recombinant 
human CK2α is able to phosphorylate the N-terminal 
acidic domain of pVHL [53] and CK2 catalytic subunits, 
rather than CK2 holoenzyme, were found important for 
triggering the HDAC-mediated pathway in HeLa cells 
[14]. Nevertheless, it is interesting to remark that in the 
present study the effects of CK2-silencing on HIFα levels 
were detected under normoxic conditions and HIF-2α 
increased in the VHL-deficient 786-O cells, what indicates 
that these effects are exerted, at least in part, through 
VHL-independent mechanisms. 
Activator of transcription STAT3 is a potent regulator 
of HIF-1α and HIF-2α expression [11] and STAT3 
phosphorylation at Tyr705 and Ser727 residues is increased 
in ccRCC tumors [13]. Previous reports have shown that 
CK2 modulates STAT3 activation since TBB  and CX-4945 
(two CK2 chemical inhibitors that block the activity of both 
CK2 holoenzyme and free catalytic subunits) diminished 
STAT3 phosphorylation on Tyr705 [17, 37] and Ser727 
[18, 19] residues triggered in response to different stimuli 
in cultured cells. STAT3 phosphorylation at Tyr705 is 
catalyzed by Jak1 or Jak2 kinases and both are activated 
by binding to CK2 [17]. Our results would point to CK2α 
rather than CK2 holoenzyme as the positive regulator of 
Tyr705-STAT3 phosphorylation since it increased upon 
CK2β downregulation both in HK-2 and 786-O cell lines. 
It must be emphasized that our present study is based on 
downregulation CK2β which did not result in decreases on 
CK2 activity measured with the CK2-standard peptide in 
contrast to that caused by the CK2 chemical inhibitors used 
in most of other previous studies.
As far as STAT3 phosphorylation on Ser727, 
overexpression of CK2 has been shown to decrease it in C6 
glioma cells through a mechanism involving CK2 activation 
of protein phosphatase PP2A [54]. On the other hand, a recent 
report has shown that recombinant human CK2 holoenzyme 
is able to directly phosphorylate ‘in vitro’ recombinant 
human STAT3, but the potential requirement of CK2β for 
this phosphorylation was not evaluated [48]. These authors 
also indicate that STAT3 phosphorylation on Ser727 in 
chronic lymphocytic leukemia (CLL) is more elaborate since 
it requires the assembly of a CK2/CD5/B-Cell Linker Protein 
(BLNK)/STAT3 complex [48]. This may underlay a unique 
targeting mechanism accounting for the phosphorylation of 
a residue, STAT3 Ser727, which is devoid of the canonical 
CK2 consensus. Interestingly, CD5 is known to interact with 
CK2 through contacts between the cytoplasmic domain of 
CD5 and the N-terminal region of CK2β [55]. The existence 
of protein complexes acting as a bridge between CK2 and 
STAT3 in renal cells is unknown. However, our results show 
that CK2β is needed for the constitutive phosphorylation of 
STAT3 on Ser727 in HK-2 cells, but this does not hold for 
786-O cells, whose constitutive pSer727-STAT3 levels do not 
seem to depend on CK2β. Although the underlying reason is 
unknown, it clearly shows a different behavior between the 
non-tumorigenic HK-2 and the tumorigenic 786-O cell lines 
concerning the potential mechanisms involved in STAT3 
phosphorylation at Ser727.
We have recently observed that STAT3 
phosphorylation both at Tyr705 and Ser727 residues is 
increased in ccRCC tumor samples, and that Ser727 is an 
independent prognostic factor in ccRCC [13]. In the present 
study we observed that the combination of p-STAT3 Ser727 
and either nuclear or cytosolic CK2α/α’ did not improve 
the prognostic values of p-STAT3 Ser727. No significant 
correlation was found between cytosolic CK2β (CK2βcyt) 
levels with patient survival, which indicates that CK2βcyt 
by itself is not useful as a prognostic biomarker. However, 
we have observed that CK2βcyt levels are instrumental to 
refine prognosis of patients with low p-STAT3 Ser727. In 
this group of patients, CK2βcyt>41 discriminates patients 
free of disease for a period of 10 years from those with 
CK2βcyt<41, which behave as the patients with p-STAT3 
Ser727 levels over 100. Therefore, CK2βcyt is useful to 
fully assess the prognosis of patients with low p-STAT3 
Ser727, because discriminates well among patients with 
different prognosis requiring different clinical follow-up 
that would be otherwise treated equally. 
MATERIALS AND METHODS
TMAs and human biopsies samples
Tissue Microarrays (TMAs) were provided by 
the Department of Pathology, Vall d’Hebron Hospital, 
Barcelona, Spain. TMAs were constructed using the 
Advanced Tissue Arrayer (Chemicon International) 
Oncotarget5747www.impactjournals.com/oncotarget
as has been detailed in previous reports [13, 56]. 98 
samples of renal cell carcinomas from patients subjected 
to a nephrectomy were included in those TMA to 
evaluate the expression of different biomarkers by 
immunohistochemistry (IHC). 21 samples from patients 
affected for ccRCC, which did not coincide with those of 
the TMA, were available for evaluating the expression of 
CK2 subunits by western-blot analysis. 
Immunohistochemistry
The tissue samples present in TMA were 
deparaffinized and an immunoperoxidase staining was 
used for the IHC analysis. Antigens were retrieved 
through a citrate buffer treatment (10 mM sodium citrate, 
pH 6.0) in a 95ºC water bath for 20 min. The endogenous 
peroxidases were blocked with Peroxidase Blocking 
Solution (3% H2O2, 10 min) and subsequently unspecific 
proteins were blocked for 1h at room temperature with 
10% Normal Horse Serum in PBST. The samples were 
incubated O/N at 4ºC with anti-CK2α/α’ (H-286, sc-
9030, Santa Cruz Biotechnology, which detects CK2α 
and CK2α’ of human origin in IHC analysis of paraffin-
embedded sections at 1:50 dilution) or anti-CK2β (6D5, 
sc-12739 1:50 dilution, Santa Cruz Biotechnology) 
antibodies. After incubation, the reaction of visualization 
was performed with Real EnVision HRP Rabbit/
Mouse Detection System (DAKO) for 40 min at room 
temperature using 3,3′-diaminobenzimide as a chromogen 
and slides finally were counterstained with haematoxylin. 
The expression levels of CK2 subunits were evaluated by 
two independent pathologists using the semi-quantitative 
method of immune-histo-score (H-score) based on the 
percentage and intensity of stained cells. Discrepancies 
were resolved by a concurrent re-examination by both 
researchers using a double-headed microscope. For each 
sample, nuclear and cytosolic CK2α and CK2β expression 
were evaluated.  The intensity score was defined as: 0 = 
non appreciable staining in cells; 1 = weak staining; 
2 = moderate staining; 3 = intense staining. [H-score = 1 
× (% weak) + 2 × (% moderate) + 3 × (% intense) ranging 
from 0 to 300]. For each patient an H-score mean of three 
cores were obtained and used for subsequent statistical 
analysis. Snapshots were taken with a Leica DFC 500 
camera coupled to a Leica DMRB microscope using the 
Leica Application Suite V4.3 software.
Cell lines and transfections
Proximal tubule epithelial cell line HK2 (CRL-
2190TM) and human renal adenocarcinoma cell line 
786-O (CRL-1932TM) were obtained from the American 
Type Culture Collection (ATCC). HK-2 and 786-O cells 
were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum 
(FBS), 1% (v/v) L-Glutamine, 1 mM sodium pyruvate, 1% 
(v/v) Streptomycin and Penicillin at 37ºC in an incubator. 
Stably-silenced cell lines for CK2α and CK2β 
subunits (shCK2α and shCK2β respectively) as well as 
control (shCV) cell lines were generated by transduction 
with Sigma Mission® lentiviral Transduction Particles 
(Sigma-Aldrich) (shCK2α: NM_177559.2-1895s21c1; 
shCK2β: NM_001320.x-823s1c1; shCV: SHC202V) at a 
final MOI (Multiplicity of Infection) of 2 and followed 
by a puromycin selection (1 μg/mL) for a week. HK-2 
and 786-O stably-silenced cell lines were maintained in 
complete DMEM medium supplemented with 1 µg/mL of 
puromycin in a cell incubator. 
Tissue and cell lysates and western blot analysis
Human renal carcinoma tissues were washed with 
cold phosphate buffered saline (PBS) and lysed in lysis 
buffer (50 mM Tris/HCl pH 7.7, 150 mM NaCl, 15 mM 
MgCl2, 0.4 mM EDTA, 0.5% Triton X-100, 0.5 mM DTT, 
2 mM PMSF, 100 µg/ml protease inhibitors). HK-2 and 
786-O cell lines extracts were obtained washing cells with 
PBS and lysed using the cell lysis buffer (50 mM Tris/
HCl pH 7.4, 150 mM NaCl, 1 % triton-X-100, 1 mM DTT, 
1 mM PMSF, 1 mM EDTA, 25 mM NaF, 0,2 mM Na2VO3, 
2 mM PPi, 1 μg/mL protease inhibitors (leupeptin, 
benzamidin, aprotinin, pepstatin)). Protein concentrations 
of the extracts were determined by the colorimetric method 
of Bradford according to the manufacturer’s instructions 
(BioRad). Equal amounts of proteins were loaded in 
10% SDS polyacrylamide gels (SDS-PAGE), subjected 
to electrophoresis and subsequently electrotransfered to 
polyvinylidene fluoride membranes (PVDF, Immobilion 
P, Millipore). Unspecific proteins were blocked in 5% non-
fat dry milk in TTBS (50 mM Tris/HCl, pH 7.4, 150 mM 
NaCl and 0.1% Tween-20) for 1h at room temperature. 
Membranes were then incubated overnight with the 
adequate primary antibodies at 4ºC, rinsed in TTBS and 
incubated with their respective secondary antibodies 
conjugated to horseradish peroxidase (HRP). The signal 
was generated using Lumi-light Western blotting substrate 
(Roche, GE) and detected by Amersham Hyperfilm ECL 
(GE-Healthcare) or Chemidoc MP Image System (Bio-
Rad, Hercules, CA). Primary antibodies used were: 
anti-CK2α H-286 (sc-9030, Santa Cruz Biotechnology), 
anti-CK2α 1AD9 (05-1431, Millipore), anti-CK2α’ 
(A300-199A, Bethyl Laboratories), anti-CK2β 6D5 (sc-
12739, Santa Cruz Biotechnology), anti-CK2β(h) (raised 
in rabbits immunized with whole human recombinant 
CK2β as described in [57]),  anti-p-Akt1 Ser129 
(ab133458, EPR6150, Abcam), anti-Akt1 (2938, C73H10, 
Cell Signaling), Anti-Akt2 (3063, D6G4, Cell Signaling), 
anti-E-Cadherin (610181, BD Biosciences), anti-Snail1 
(3895, L70G2, Cell Signaling), anti-Vimentin (V6389 
Sigma-Aldrich), anti-p-STAT3 Tyr705 (4113, M9C6, Cell 
Signaling), anti-p-STAT3 Ser727(9134, Cell Signaling), 
anti-STAT3 (9139, 124H6, Cell Signaling), anti-HIF-1α 
(ab82832, Abcam), anti-HIF-2α (ab199, Abcam), anti-β-
actin (sc-47778, Santa Cruz Biotechnology). Secondary 
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antibodies were obtained from Bio-Rad: IgG Goat Anti-
Rabbit IgG (H+L)-HRP conjugate (170-6515, BioRad) 
and IgG Goat-Anti Mouse IgG (H+L)-HRP conjugate 
(170-6516, BioRad). 
Protein kinase activity assay
Protein kinase CK2 activity was determined in cell 
extracts using either the CK2 specific peptide (CK2-tide: 
RRRADDSDDDDD) or the eIF2β-derived peptide (eIF2β-
tide: MSGDEMIFDPTMSKKKKKKKKP) as substrates, 
in the presence of phosphorylation mixture as described 
previously [30]. The activity exhibited by the catalytic 
subunits (CK2α/α’) alone was also determined by in-
gel activity assays. Cell lysates were run on an 11% 
polyacrylamide gel electrophoresis containing β-casein 
(0.5 mg/ml) in the running and the stacking gel. After 
protein separation, proteins on the gel were renatured 
and then the gel were incubated with the phosphorylation 
medium containing 1 mM [γ33P]ATP [52]. The gel 
was stained with Comassie, dried and analyzed by 
autoradiography (CyclonePlus Storage Phosphor System, 
PerkinElmer).
Statistical analysis
Statistical Analysis was performed using GraphPad 
Prism 5 program for Windows. One-way ANOVA with a 
Tukey’s post-hoc test was used to analyze the relationships 
between CK2α and CK2β expression levels in TMAs. 
Associations between pSTAT3 S727 and CK2β expression 
and clinicopathologic parameters were evaluated with 
the nonparametric Mann–Whitney U test. Disease-free 
survival was calculated as the date of surgery to the date of 
loco-regional or distant recurrence. Subsequently, Kaplan– 
Meier survival estimates were compared using the log-
rank test. Multivariate analysis was performed using a Cox 
regression model to estimate the independent prognostic 
importance of clinicopathologic parameters. Statistical 
analysis was performed with the Statistical Package for 
Social Sciences, version 12 software (SPSS).
Student’s t-test was used to analyze CK2 subunits 
expression in ccRCC tumor samples by WB analyses 
as well as the cell growth and the expression and 
phosphorylation of the different proteins in the CK2-
silenced cell. Statistical significance was set at (*) p < 
0.05, (**) p <0.01, (***) p < 0.001, and (****) p < 0.0001.  
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